The D-Lay MS clinical trial in France found that high-dose oral cholecalciferol reduced disease activity in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, with low risk of adverse events. This vitamin D supplementation may be a promising candidate for further therapeutic strategy studies in managing multiple sclerosis.

Source: JAMA